Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Chaccour
 
NCT04390022
RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 outpatients meta-analysis

ACTIV-6 (ivermectine)
 
NCT04885530
RCTivermectinplaceboCOVID 19 outpatientslow
602/604 inconclusive
    ACTIV 6 ivermectin
     
    NCT04885530
    RCTivermectinplaceboCOVID 19 outpatientslow
    817/774 inconclusive
      ACTIV-6
       
      NCT04885530
      RCTfluvoxamineplaceboCOVID 19 outpatientslow
      674/614 inconclusive
      • inconclusive 4 % decrease in recovery (PE) with a high degree of certainty due to low risk of bias
      COVID-OUT (fluvoxamine)
       
      NCT04510194
      RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
      334/327 inconclusive
      • inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
      COVID-OUT (ivermectin)
       
      NCT04510194
      RCTivermectinplaceboCOVID 19 outpatientssome concern
      410/398 inconclusive
        TOGETHER (ivermectine)
         
        NCT04727424
        RCTivermectinplaceboCOVID 19 outpatientslow
        679/679 inconclusive
        • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
        ACTION
         
        NCT04332107
        RCTazithromycinplaceboCOVID 19 outpatientssome concern
        171/92 inconclusive
        • inconclusive 1 % increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        The original primary outcome was changed given the lower risk of hospitalization and slower than anticipated enrollment.
        EPIC-HR
         
        NCT04960202
        RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 outpatientslow
        1120/1126 conclusif
        • demonstrated 88 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 96 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
        • statistically significant 76 % increase in related AE (TRAE) with a high degree of certainty due to low risk of bias
        Based on laboratory studies only, Paxlovid is also expected to be active against Omicron and other variants.
        Fischer (all doses)
         
        NCT04405570
        RCTmolnupiravirplaceboCOVID 19 outpatientssome concern
        140/62 suggested
        • suggested 13.5-fold increase in viral clearance ,viral clearance by day 7 with a moderate degree of certainty due to some concern in risk of bias
        Hinks (ATOMIC2)
         
        NCT04381962
        RCTazithromycinstandard of careCOVID 19 outpatientssome concern
        147/148 inconclusive
        • inconclusive 9 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
        Lopez-Medina
         
        NCT04405843
        RCTivermectinplaceboCOVID 19 outpatientssome concern
        200/200 inconclusive
        • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        MOVe-OUT
         
        NCT04575597
        RCTmolnupiravirplaceboCOVID 19 outpatientslow
        716/717 conclusif
        • demonstrated 52 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 51 % decrease in hospitalization with a high degree of certainty due to low risk of bias
        PINETREE (GS-US-540-9012)
         
        NCT04501952
        RCTremdesivirplaceboCOVID 19 outpatientslow
        292/292 conclusif
        • demonstrated 87 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 72 % decrease in hospitalization with a high degree of certainty due to low risk of bias
        PRINCIPLE
         
        ISRCTN86534580
        RCTazithromycinstandard of careCOVID 19 outpatientssome concern
        540/875 inconclusive
        • inconclusive 8 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • inconclusive 6 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
        Reis (Lopinavir-ritonavir) (TOGETHER)
         
        NCT04403100
        RCTlopinavir/ritonavirplaceboCOVID 19 outpatientssome concern
        244/227 inconclusive
          TOGETHER
           
          NCT04727424
          RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
          741/756 suggested
          • suggested 36 % decrease in clinical deterioration,emergency room observation for > 6 hours or hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
          IVERCORCOVID19 (Vallejos)
           
          NCT04529525
          RCTivermectinplaceboCOVID 19 outpatientslow
          250/251 inconclusive
          • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
          Lenze (STOP COVID 1)
           
          NCT04342663
          RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
          80/72 conclusif
          • demonstrated 93 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
          Roozbeh
           
          IRCT20200403046926N1
          RCTsofosbuvir and daclatasvirstandard of careCOVID 19 outpatients
          bias due to missing outcome data some concern
          bias in measurement of the primary outcome some concern
          bias in selection of the reported result some concern
          " >some concern
          30/30 inconclusive 7 studies excluded by filtering options (5 RCT / 2 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).